Literature DB >> 21898549

p38 MAPK activation, JNK inhibition, neoplastic growth inhibition, and increased gap junction communication in human lung carcinoma and Ras-transformed cells by 4-phenyl-3-butenoic acid.

Diane F Matesic1, Tatyana S Sidorova, Timothy J Burns, Allison M Bell, Paul L Tran, Randall J Ruch, Sheldon W May.   

Abstract

Human lung neoplasms frequently express mutations that down-regulate expression of various tumor suppressor molecules, including mitogen-activated protein kinases such as p38 MAPK. Conversely, activation of p38 MAPK in tumor cells results in cancer cell cycle inhibition or apoptosis initiated by chemotherapeutic agents such as retinoids or cisplatin, and is therefore an attractive approach for experimental anti-tumor therapies. We now report that 4-phenyl-3-butenoic acid (PBA), an experimental compound that reverses the transformed phenotype at non-cytotoxic concentrations, activates p38 MAPK in tumorigenic cells at concentrations and treatment times that correlate with decreased cell growth and increased cell-cell communication. H2009 human lung carcinoma cells and ras-transformed rat liver epithelial cells treated with PBA showed increased activation of p38 MAPK and its downstream effectors which occurred after 4 h and lasted beyond 48 h. Untransformed plasmid control cells showed low activation of p38 MAPK compared to ras-transformed and H2009 carcinoma cells, which correlates with the reduced effect of PBA on untransformed cell growth. The p38 MAPK inhibitor, SB203580, negated PBA's activation of p38 MAPK downstream effectors. PBA also increased cell-cell communication and connexin 43 phosphorylation in ras-transformed cells, which were prevented by SB203580. In addition, PBA decreased activation of JNK, which is upregulated in many cancers. Taken together, these results suggest that PBA exerts its growth regulatory effect in tumorigenic cells by concomitant up-regulation of p38 MAPK activity, altered connexin 43 expression, and down-regulation of JNK activity. PBA may therefore be an effective therapeutic agent in human cancers that exhibit down-regulated p38 MAPK activity and/or activated JNK and altered cell-cell communication.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21898549      PMCID: PMC3893766          DOI: 10.1002/jcb.23353

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  54 in total

1.  Role of the p38 MAPK pathway in cisplatin-based therapy.

Authors:  Javier Hernández Losa; Carlos Parada Cobo; Juan Guinea Viniegra; Victor Javier Sánchez-Arevalo Lobo; Santiago Ramón y Cajal; Ricardo Sánchez-Prieto
Journal:  Oncogene       Date:  2003-06-26       Impact factor: 9.867

2.  A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis.

Authors:  Oleg Timofeev; Ting Yi Lee; Dmitry V Bulavin
Journal:  Cell Cycle       Date:  2005-01-30       Impact factor: 4.534

3.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

Review 4.  Role of connexin genes in growth control.

Authors:  H Yamasaki; C C Naus
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

5.  A diploid epithelial cell line from normal adult rat liver with phenotypic properties of 'oval' cells.

Authors:  M S Tsao; J D Smith; K G Nelson; J W Grisham
Journal:  Exp Cell Res       Date:  1984-09       Impact factor: 3.905

Review 6.  The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Authors:  Robert L Comis
Journal:  Oncologist       Date:  2005-08

Review 7.  p38 MAP kinase: a convergence point in cancer therapy.

Authors:  James M Olson; Andrew R Hallahan
Journal:  Trends Mol Med       Date:  2004-03       Impact factor: 11.951

8.  Elevated JNK activation contributes to the pathogenesis of human brain tumors.

Authors:  Marc A Antonyak; Lawrence C Kenyon; Andrew K Godwin; David C James; David R Emlet; Isamu Okamoto; Mehdi Tnani; Marina Holgado-Madruga; David K Moscatello; Albert J Wong
Journal:  Oncogene       Date:  2002-08-01       Impact factor: 9.867

9.  Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma.

Authors:  Kenya Iyoda; Yutaka Sasaki; Masayoshi Horimoto; Takashi Toyama; Takayuki Yakushijin; Mitsuru Sakakibara; Tetsuo Takehara; Jiro Fujimoto; Masatsugu Hori; Jack R Wands; Norio Hayashi
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

10.  Restoration of gap-junctional intercellular communication in a communication-deficient rat liver cell mutant by transfection with connexin 43 cDNA.

Authors:  Y S Jou; D Matesic; E Dupont; S C Lu; H L Rupp; B V Madhukar; S Y Oh; J E Trosko; C C Chang
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

View more
  11 in total

1.  Comparative effects of 4-phenyl-3-butenoic acid and vorinostat on cell growth and signaling.

Authors:  Timothy J Burns; Amna Ali; Diane F Matesic
Journal:  Anticancer Res       Date:  2015-02       Impact factor: 2.480

2.  GATA-3 augmentation down-regulates Connexin43 in Helicobacter pylori associated gastric carcinogenesis.

Authors:  Xiaoming Liu; Ke Cao; Canxia Xu; Tingzi Hu; Li Zhou; Dan Cao; Jing Xiao; Ling Luo; Yinjie Guo; Yong Qi
Journal:  Cancer Biol Ther       Date:  2015-04-22       Impact factor: 4.742

3.  Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties.

Authors:  Amna Ali; Timothy J Burns; Jacob D Lucrezi; Sheldon W May; George R Green; Diane F Matesic
Journal:  Invest New Drugs       Date:  2015-06-13       Impact factor: 3.850

4.  Involvement of connexin43 in the infrasonic noise-induced glutamate release by cultured astrocytes.

Authors:  Shan Jiang; Yong-Qiang Wang; Cheng-Feng Xu; Ya-Na Li; Rong Guo; Ling Li
Journal:  Neurochem Res       Date:  2014-03-15       Impact factor: 3.996

5.  A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies.

Authors:  Diane F Matesic; Amna Ali; Tatyana S Sidorova; Timothy J Burns
Journal:  Curr Bioact Compd       Date:  2013

6.  Inhibition of JNK and p38 MAPK phosphorylation by 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester and 4-phenyl-butenoic acid decreases substance P-induced TNF-α upregulation in macrophages.

Authors:  Jacob D Lucrezi; Timothy J Burns; Diane F Matesic; Charlie D Oldham; Sheldon W May
Journal:  Int Immunopharmacol       Date:  2014-04-18       Impact factor: 4.932

7.  Post-ovulatory aging of oocytes disrupts kinase signaling pathways and lysosome biogenesis.

Authors:  Lynda K McGinnis; Steven Pelech; William H Kinsey
Journal:  Mol Reprod Dev       Date:  2014-09-19       Impact factor: 2.609

8.  (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-κB and up-regulation of TNFRSF10B (DR5).

Authors:  Pushpa Saranya Kollipara; Heon Sang Jeong; Sang Bae Han; Jin Tae Hong
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  All-trans retinoic acid arrests cell cycle in leukemic bone marrow stromal cells by increasing intercellular communication through connexin 43-mediated gap junction.

Authors:  Yao Liu; Qin Wen; Xue-Lian Chen; Shi-Jie Yang; Lei Gao; Li Gao; Cheng Zhang; Jia-Li Li; Xi-Xi Xiang; Kai Wan; Xing-Hua Chen; Xi Zhang; Jiang-Fan Zhong
Journal:  J Hematol Oncol       Date:  2015-10-07       Impact factor: 17.388

10.  Curcumol Inhibits Growth and Induces Apoptosis of Colorectal Cancer LoVo Cell Line via IGF-1R and p38 MAPK Pathway.

Authors:  Juan Wang; Fengxiang Huang; Zhun Bai; Bixia Chi; Jiacai Wu; Xu Chen
Journal:  Int J Mol Sci       Date:  2015-08-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.